UCLA conducts research for a wide range of medical disorders and offers patients opportunities to participate in research and clinical trials.
Visit our Office of Clinical Trials website for more information about clinical trials.
Below are some featured trials at UCLA. Click here for a PDF of these trials. You may also visit the links to the right for additional trials from our clinical departments.
Information for Participants (UCLA OHRPP)
Understanding Clinical Trials (ClinicalTrials.gov)
UCLA Cancer Trials (UCLA JCCC)
Link to Non-Cancer Trials at UCLA
The Aftercare Research Program at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA provides free assessment and treatment for participants in clinical research studies designed to improve understanding of psychotic disorders and develop more effective treatments. An initial diagnostic interview will determine a patient’s eligibility. The study will include cognitive training, individual case management, group therapy and antipsychotic medication. Patients’ family members will be invited to join family psychoeducational meetings. Info: (310) 206-3142 or email@example.com or firstname.lastname@example.org or www.semel.ucla.edu/aftercare.
This research study seeks candidates to participate in a research study to determine if cognitive training and physical exercise intervention can improve mental performance and reduce cardiovascular risk factors for memory problems. This study will last six months. All visits will take place at UCLA or at the YWCA in Santa Monica. Participants will be asked to join a twice-weekly program over the course of three months. This program involves fitness and clinical assessments to measure physical health, physical training, cognitive assessment and training, nutritional counseling and coaching, and five activitymonitoring sessions. Info: (310) 206-1319 or email@example.com.
The CONNECT study will test whether an oral, experimental drug, AZD0530 (saracatinib), slows progression in mild-stage Alzheimer’s disease (AD). Researchers will use position emission tomography (PET) imaging to evaluate whether the drug is effective in slowing decline in brain metabolism and whether it is safe and well tolerated in patients with AD. Screening will occur over six weeks followed by a 52-week treatment period. The study requires a minimum of four visits during the screening and 13 to 14 visits during the course of the treatment. Info: (310) 794-6191 or firstname.lastname@example.org.
The “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease” (A4) study is a clinical study for individuals 65 to 85 years old who have normal thinking and memory function but who may be at risk for developing Alzheimer’s disease (AD) in the future. The A4 study is for people without any outward signs of AD, and is designed to evaluate the effectiveness, safety and tolerability of an investigational drug for AD. The purpose of the study is to test whether a new investigational treatment can slow the memory loss caused by AD. The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people. Participants will be assigned randomly to receive either the investigational drug or a placebo (inactive substance). The A4 study lasts for three years. Info: (310) 794-6191 or email@example.com.
The Mary S. Easton Center for Alzheimer’s Disease Research at UCLA is currently participating in a Phase III clinical trial sponsored by Merck & Co. of the investigational drug MK-8931. MK-8931 reduces levels of the beta amyloid protein by inhibiting the activity of an enzyme called beta secretase. MK-8931 is an oral medication taken daily. The study will last approximately two years, with roughly 12 study visits. Participants will be randomly assigned to the active study medication (MK-8931) or placebo (inactive substance). Participants will have a 66 percent chance of receiving the active study medication. Individuals ages 50 to 85 who have a memory problem are potentially eligible for this study. Info: (310) 794-6191 or firstname.lastname@example.org.
For those who are suffering from feelings of depression, sadness, hopelessness, memory loss, concentration difficulties, lack of energy, or loss of interest and pleasure in activities, UCLA is conducting a 12-month research study using an experimental combination of two drugs and a placebo (inactive substance). The study seeks participants 60 years of age and older who are not currently receiving any psychiatric treatment with medications. Medical and psychiatric evaluations and limited physical exams are provided as a part of the study. Participants will undergo PET and MRI scans. Evaluations and study medications are provided at no charge. Info: (310) 794-9523
Physical exercise has been shown to improve memory, including in the elderly. Drugs developed to stop the underlying disease processes that cause Alzheimer’s disease (AD) may not improve memory without efforts to stimulate brain function. The study will test the clinical benefits of curcumin, a safe and effective compound isolated from the turmeric root, which has been found to inhibit several potential disease pathways in AD. The study also will determine how the addition of a physical exercise program in individuals with earl memory problems may affect memory function or brain imaging and blood-based markers associated with AD. Info: (310) 478-3711 ext 48625 or (310) 478-3711 ext 42171 or VAMemoryResearch@gmail.com.
UCLA is seeking participants 60 years of age or older who are on stable medications for depression and are suffering from depressive symptoms and lack of energy to participate in a six-month research study. The trial involves 12 weekly 60-minute sessions of either a health and education wellness class or a Tai-Chi class. Participants will undergo two functional MRI scans and a complete psychiatric evaluation. Participants will be compensated. Info: (310) 983-3375
For those who are suffering from feelings of depression, sadness, hopelessness, memory loss, concentration difficulties, lack of energy or loss of interest and pleasure in activities, UCLA is conducting a 12-month research study comparing levomilnacipran (FETZIMA) to placebo (inactive substance) for treatment of geriatric depression. If you are 60 years of age or older, you may qualify. A complete psychiatric evaluation, physical exam and one MRI scan are provided. You will be compensated up to $200 and parking will be reimbursed. Info: (310) 794-9523 or (310) 794-4619
UCLA researchers are seeking women with and without polycystic ovary syndrome (PCOS) who are Caucasian and non-Hispanic, between the ages of 18 and 35, have a body-mass index between 18.5 and 25 and have not used hormones (i.e., birth control pills or a Mirena IUD) for the past three months. Participants will receive extensive free medical testing, including blood-hormone measurements, diabetes screening and ovarian and fat assessments. A small amount of fat will be removed from the abdomen and blood will be drawn for research purposes. Only women with PCOS will take an oral pill that contains either the drug Flutamide or a placebo (inactive substance) for six complete 28-day cycles. The free medical testing will be repeated at the end of the study. Women without PCOS may earn up to $300 and women with PCOS may earn up to $840. Info: (310) 825-7301 or Health4Women@mednet.ucla.edu.
The UCLA Longevity Center is studying the effects of pomegranate juice on memory. Volunteers between the ages of 50 and 75 are needed. The study will last one year and includes five visits to UCLA and $300 compensation for participation. Info: (310) 825-0545
UCLA researchers are seeking women ages 18 to 55 to help understand brain activity changes associated with a chronic-pain condition called vulvodynia. Women who have been diagnosed with vulvodynia or vestibulodynia, or those with chronic pain around the opening of the vagina with or without intercourse, may be eligible to participate. Participation includes a pelvic exam, sensitivity testing, one small blood sample and one MRI scan. Volunteers can earn up to $210 for participating. Info: (310) 825-5255 or email@example.com.
Aspirin is a mainstay therapy for patients with atherosclerotic cardiovascular disease (ASCVD). To identify the optimal dose of aspirin for secondary prevention in patients with ASCVD, UCLA will participate in a pragmatic clinical trial in which 20,000 patients who are at high risk for ischemic events will be recruited and randomly assigned to receive an aspirin dose of 81 mg/day or 325 mg/day. The goals of the ADAPTABLE study include: 1) comparing the effectiveness of two different doses of aspirin, and 2) comparing the effects of aspirin in selected subgroups of patients (e.g., women vs. men, older vs. younger patients, racial minority patients vs. white patients, patients with vs. without diabetes, and patients with vs. without chronic kidney disease). Info: 310-794-8502 or firstname.lastname@example.org.
The Addictions Research Laboratory in the Department of Psychology at UCLA is looking for individuals, age 21 to 55, who smoke cigarettes and drink alcohol heavily to participate in a study investigating a combination of medications (varenicline and naltrexone) for heavy drinking smokers. This study involves taking medication for 14 weeks in addition to 12 in-person visits over 7 months. During these visits, you will be asked to complete questionnaires about your health and drinking and smoking habits. Participants will be compensated up to $320 for participation. Info: (310) 206-6756.
UCLA is seeking healthy men and women between the ages of 21-45 for a research study on the effect of E-cigarettes on blood vessel function. The study will involve 4, 2 hour visits.Must be an E-Cigarette user, or a non-smoker. Monetary compensation provided. Info: (310) 825-3510 or email@example.com.
UCLA is seeking adults between the ages of 18 and 65 with a history of vestibular migraine (VM) – a recently recognized type of migraine headache that causes attacks of vertigo and dizziness – to participate in a research study. Participants will undergo an observation phase and a treatment phase. While in the study, participants will need to document how often they get VM and track five of their last episodes in a diary. The study includes up to three visits and $50 in compensation per visit. Info: (310) 206-8511